GANT61 surmounts drug resistance of ADR by upregulating lysosome activities and reducing BCL2 expression in HL-60/ADR cells
GANT61 effectively reversed ADR resistance in HL-60/ADR cells by upregulating lysosome activities and downgrading BCL2 expression, providing a new treatment strategy with acceptable toxicity for AML-resistant patients.
Authors
- Liang Zhao (ORCID: https://orcid.org/0000-0002-8077-4510)
- Ming Zhou (ORCID: https://orcid.org/0000-0002-5649-8106)
- Jiangwen Long
- Haiyan Wu (ORCID: https://orcid.org/0000-0001-5322-3425)
- Yang Shi (ORCID: https://orcid.org/0000-0001-6486-4340)
- Can Liu (ORCID: https://orcid.org/0000-0001-5521-3335)
- Guanghua Liu (ORCID: https://orcid.org/0000-0001-9692-5857)
- Cheng Zhou (ORCID: https://orcid.org/0000-0002-6302-5235)
Institutions
- Central South University (CN)
- Hunan Normal University (CN)
- Hunan Provincial People's Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1186/s12935-024-03626-5
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hainan Province